FindTrial
Sign In

Clinical Observation for The Therapeutic Effect Of Recombinant Human Epidermal Growth Factor In Treatment of Radiodermatitis After Radiotherapy For Rectal Cancer

Clinical Observation for The Therapeutic Effect Of Recombinant Human Epidermal Growth Factor In Treatment of Radiodermatitis After Radiotherapy For Rectal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020842
Enrollment
Unknown
Registered
2019-01-20
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radiodermatitis

Interventions

Group1:physiological saline plus rhEGF
Group2:physiological saline

Sponsors

The Sixth Affiliated Hospital of SUN YAT-SEN University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed as rectal adenocarcinoma, clinical stage T3-4/N+, or recurrent rectal adenocarcinoma requires radiotherapy.

Exclusion criteria

Exclusion criteria: Received radiotherapy before this trial, or radiotherapy target is significantly biased to one side.

Design outcomes

Primary

MeasureTime frame
the time of dermatitis appear on about perianal, perineal and inguinal skin;the healing time of dermatitis around the anus, about perineum and inguinal skin;—

Countries

China

Contacts

Public ContactZheng Jian

Department of Radiotherapy, The Sixth Affiliated Hospital of Sun Yat-Sen University

yingjuxchzh@163.com+86 13688873757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026